Week of 27 July 2026

Two anchor posts on pharma commercialisation (market access as a starting point, and three myths about rare/GI launches), one AI-in-healthcare carousel on vetting pilots, and a rotating slot on generational differences in health marketing. The through-line is the gap between what looks rigorous and what actually changes a decision. No product, efficacy or off-label claims; all figures kept qualitative.

Images weren’t auto-generated this run — each post carries a ready-to-paste prompt instead.

• #1Skipped
  Pharma & regulatoryContrarian take

  Access isn't the last hurdle — it's the starting line

  The best launch plan I saw this year had almost nothing to do with the drug.

  Tue · 07:30-09:00

  1,180 / 3,000 · folds at ~210

  
• #2Skipped
  AI in healthcareFramework / how-tocarousel

  6 questions to ask before you fund another AI pilot

  Most "AI in pharma" pilots quietly die in month four. Here's the pattern I keep seeing.

  Wed · 12:00-13:00

  559 / 3,000 · folds at ~210

  
• #3Skipped
  Pharma & regulatoryMyth-buster

  Three myths about commercialising rare & GI medicines

  "Rare disease means small commercial thinking." That myth costs patients years.

  Thu · 07:30-09:00

  1,173 / 3,000 · folds at ~210

  no image
• #4Skipped
  Marketing across the generationsTrend breakdown

  One health message, four definitions of "trust"

  A Boomer and a Gen Z shopper can buy the same supplement for completely opposite reasons.

  Fri · 12:00-13:00

  1,141 / 3,000 · folds at ~210